Korea Research Institute of Bioscience and Biotechnology

Enzychem Lifesciences Corporation

Ho Bum Kang

Kyung Seop Ahn

Jae Wha Kim

Sei Ryang Oh

Ki-Young Sohn

Yong-Hae Han

Tae Suk Lee

Jong Koo Kang

Sei-Ryang Oh

Myung Hwan Kim

Jae Min Shin

Young Eun Ko

Da Jung Ji

Hyeong Kyu Lee

Ok-Kyoung Kwon

Doo Young Kim

Ki Young Sohn

Young Sik Jung

Hee Gu Lee

Hyun Woo Oh

Tae-Suk Lee

Seung Ho Kim

Beom Su Park

JongKoo Kang

Hyuk Hwan Song

Jae Sung Song

Joo Heon Kim

Hye Kyung Kim

Khiev Piseth

Byeong Hwa Jeon

Jang Mi Son

Yi Hua Pei

Jae Mine Yoo

Jang Mi Sun

Jae Jong Go

Jin Soo Yook

Da Chung Ji

Jongkoo Kang

The present invention relates to a composition containing a monoacetyldiglyceride compound as an active ingredient, for inhibiting blood cancer or metastasis, and a use thereof. The monoacetyldiglyceride compound according to the present invention has excellent effects of inhibiting the expression of IL-4 and inhibiting the activity of STAT-6, and thereby is capable of overcoming side effects of currently used blood cancer or metastasis inhibiting agents. Also, the monoacetyldiglyceride compound is a non-toxic compound having superior therapeutic effects and thus can be useful as a composition for preventing, treating, or improving blood cancer and metastasis.

Composition containing monoacetyldiacylglycerol compound as active ingredient for inhibiting blood cancer or metastasis

The invention relates to pharmaceutical compositions, as well as health functional food compositions and quasi-drug compositions, for preventing, treating, or improving rheumatoid arthritis, comprising a monoacetyldiacylglycerol compound as an active ingredient. The monoacetyldiacylglycerol of the invention is effective in inhibiting the phosphorylation of STAT-3 known to be a therapeutic target for rheumatoid arthritis. As the monoacetyldiacylglycerol is an effective therapeutic agent without toxicity, the monoacetyldiacylglycerol can overcome the side effects of the medicines currently used in the treatment of rheumatoid arthritis. Thus, the monoacetyldiacylglycerol can be used for preventing, treating or improving rheumatoid arthritis.

Compositions containing monoacetyldiacylglycerol compound as an active ingredient for preventing or treating rheumatoid arthritis

The present invention relates to a pharmaceutical composition, functional health food composition, quasi-drug composition, and cosmetic composition containing a monoacetyldiacylglycerol compound as an active ingredient for preventing, treating or improving atopic dermatitis. The monoacetyldiacylglycerol compound of the present invention has an excellent effect of suppression of IL-4 and IgE secretion, thereby overcoming side effects of an atopic dermatitis treatment agent currently in use, having no toxicity, and exhibiting an excellent treatment effect, and thus can be useful as a composition for preventing, treating, and ameliorating atopic dermatitis.

Composition containing monoacetyldiglyceride compound as active ingredient for preventing or treating atopic dermatitis

The present invention relates to a pharmaceutical composition for the prevention or treatment of atopy comprising the extract of, the fraction thereof, of the compound isolated from the same as an active ingredient. More precisely, the extract of, the fraction thereof, or the compound isolated from the same, genekwadapnin or yuanhuacine, of the present invention can increase the secretion of cytokine in Th1 immune cells and suppress atopy in the atopy mouse model, so that the extract of, the fraction thereof, or the compound isolated from the same of the present invention can be effectively used for the prevention or treatment of atopy.

Daphne genkwa extracts, and pharmaceutical composition containing fractions of the extracts or compounds separated from the extracts as active ingredients for preventing or treating atopic dermatitis

The present invention relates to a diterpene compound derived from, and a pharmaceutical composition for treating or preventing viral infectious diseases, a health functional food for preventing or ameliorating viral infectious diseases and a composition for enhancing the production of interferon-gamma, which comprise the diterpene compound. Furthermore, the present invention relates to a method for preventing or treating viral infectious diseases including administering the composition to a subject having a viral infectious disease occurrence or a risk thereof with a therapeutically effective dose.

Phorbol type diterpene compound, pharmaceutical composition for treatment or prevention of viral infectious diseases including same

The present invention relates to a pharmaceutical composition for treating wounds or revitalizing skin comprising theextract, the fractions thereof, or the diterpene compound isolated therefrom as an active ingredient. Theextract may act on epithelial cells to induce PKD1 activity required for improving the reproduction capability of differentiated epithelial cells, and thus may induce the phosphorylation of lower ERK1 and the generation of Cycline D, thus exhibiting an excellent ability to activate the reproduction of damaged skin. Therefore, theextract may be used effectively as an active ingredient in a pharmaceutical composition for treating wounds or reproducing skin, a health food for recovering skin damage or reproducing skin, or a functional cosmetic for inducing skin cell activity.

[object Object]

Growing community of inventors

Daejeon, South Korea

Ho Bum Kang